Global Spine Journal · Nov 16, 2026

The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Spinal Surgery: A Systematic Review and Meta-Analysis

By Xu X, Zhang X, Cai Z et al.

Study design: systematic review and meta-analysis. Objective: To evaluate the association between perioperative glucagon-like peptide-1 receptor agonists (GLP-1RAs) use and clinical outcomes after spine surgery. Methods: PubMed, MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through July 31, 2026. Comparative studies of adults undergoing spine surgery with versus without perioperative GLP-1RA exposure were pooled using random-effects models. Risk of bias was assessed with the Newcastle-Ottawa Scale and certainty with GRADE. Results: Thirty-six retrospective cohorts involving 435,085 patients were included. GLP-1RA use was not associated with pseudarthrosis at 90 days (RR, 0.99; 95% CI, 0.25-3.98), but was associated with lower risk at 6 months (RR, 0.62; 95% CI, 0.56-0.68), 1 year (RR, 0.65; 95% CI, 0.61-0.69), 2 years (RR, 0.77; 95% CI, 0.66-0.89), and 3 years (RR, 0.80; 95% CI, 0.69-0.92). Revision risk was lower at 6 months and 2 years. GLP-1RA use was also associated with lower risks of selected systemic, infectious, and wound complications and reduced healthcare utilization, but with higher risks of hypoglycemia and adjacent segment disease. Conclusions: In separate follow-up-specific analyses, GLP-1RA exposure was associated with lower pseudarthrosis and revision risks at selected intervals and with several other postoperative outcomes. These estimates do not establish a temporal drug effect or distinguish direct pharmacologic effects from weight loss, improved glycemic control, or confounding. Heterogeneity, possible overlapping cohorts, and very-low-certainty observational evidence preclude causal or treatment recommendations.

doi.org/10.1177/21925682261509580PubMed 43038446Interventions

AgingResearch.News